ONVO - Organovo Holdings, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.2905
-0.0095 (-3.17%)
At close: 4:00PM EDT

0.2905 0.00 (0.00%)
After hours: 4:30PM EDT

Stock chart is not supported by your current browser
Previous Close0.3000
Open0.2966
Bid0.2905 x 2900
Ask0.2950 x 800
Day's Range0.2850 - 0.3000
52 Week Range0.2200 - 1.3400
Volume418,250
Avg. Volume2,617,821
Market Cap37.846M
Beta (3Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Organovo to Explore Strategic Alternatives and Implement Restructuring Plan

    Organovo Holdings, Inc. (ONVO) (“Organovo”) today announced that it has engaged Roth Capital Partners (“Roth”) as its financial advisor to assist in the exploration of strategic alternatives. This decision was reached by Organovo’s board of directors after concluding that the Company had not generated decisive scientific data supporting the prolonged functionality and therapeutic benefit of its lead therapeutic liver tissue candidate, and that the necessary redevelopment of the tissue would require significant time, additional resources and development risks, and would likely not provide sufficient return on investment for the Company’s stockholders. To support the range of strategic alternatives being explored, the Company is also implementing a restructuring plan to significantly reduce expenses associated with its lead program in order to preserve cash.

  • GlobeNewswire

    Organovo Announces Release Date for Fiscal First-Quarter 2020 Financial Results

    SAN DIEGO, July 18, 2019 -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, August 8, 2019 at 5:00 p.m. Eastern Time (ET) to discuss.

  • GlobeNewswire

    Organovo Presents Data on Creating Stem Cell-Based Bioprinted Kidney Organoids at the International Society for Stem Cell Research (ISSCR) 2019 Annual Meeting

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious diseases, presented data on fabricating stem cell-based kidney tissues at The International Society for Stem Cell Research 2019 Annual Meeting held in Los Angeles, Ca. Organovo has continued to adapt stem-cell based approaches to developing kidney tissues using its leading 3D bioprinting platform.  The Company has demonstrated the automated production of complex kidney organoids, with potential future applications including in vitro disease modeling and the treatment of patients with renal disease.

  • GlobeNewswire

    Organovo to Present at Raymond James Life Sciences and MedTech Conference

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that Chief Executive Officer Taylor J. Crouch is scheduled to speak at the Raymond James Life Sciences and MedTech Conference in New York on Tuesday, June 18, 2019 at 1:15pm Eastern Time (ET).  The presentation will be simultaneously audio webcast at http://www.organovo.com.  The audio webcast will be archived for seven days following the conference.

  • GlobeNewswire

    Organovo Collaborates With MCRI and Leiden University Medical Center to Develop Stem Cell-Based Bioprinted Tissue Treatments for Kidney Disease

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious diseases, today announced a collaboration with Professor Melissa Little at the Murdoch Children's Research Institute (“MCRI”), The Royal Children’s Hospital, Melbourne, Australia and Ton Rabelink at Universiteit Leiden (“LUMC”), Leiden, Netherlands. The project will expand the use of 3D bioprinted stem cell-based therapeutic tissues to applications aimed at treating end-stage renal disease.  This multi-organizational effort integrates Organovo’s leading bioprinting platform with MCRI’s advanced stem cell differentiation technology and LUMC’s cell lines and clinical expertise.  The collaboration has been made possible through generous funding from Stem Cells Australia and CSL Limited.

  • GlobeNewswire

    Organovo Updates Key Clinical Development Goals; Company Reports Preliminary Fiscal Fourth-Quarter 2019 Results

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today updated its key clinical development goals and reported its preliminary fiscal fourth-quarter 2019 financial results.

  • GlobeNewswire

    Organovo Announces Release Date for Preliminary Fiscal Fourth-Quarter 2019 Financial Results

    SAN DIEGO, May 17, 2019 -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Wednesday, May 22, 2019 at 5:00 p.m. Eastern Time (ET) to discuss.

  • GlobeNewswire

    Organovo to Present at 2019 Cell & Gene Meeting on the Mediterranean

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that Chief Medical Officer, Dr. Steven G. Hughes, is scheduled to speak at the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 in Barcelona, Spain. Organovo is changing the shape of life science research and transforming medical care.

  • GlobeNewswire

    Organovo to Participate in Nash Panel Discussion at 31st Annual Roth Conference

    Organovo Holdings, Inc. (ONVO) (“Organovo”) today announced that it will participate in a panel at the 31st Annual ROTH Conference, being held in Laguna Niguel, Ca. from March 17-19, 2019.  The Company will also participate in one-on-one meetings with investors who are registered to attend the conference.

  • GlobeNewswire

    Organovo Appoints New Board Member

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that its board of directors has appointed one new member.  Ms. Carolyn Beaver, former Chief Financial Officer of Sequenom Inc., will join Organovo’s board, effective immediately.  Ms. Beaver’s appointment increases the number of Organovo directors to nine.

  • GlobeNewswire

    Factors of Influence in 2019, Key Indicators and Opportunity within Fiserv, DTE Energy, Acacia Communications, Organovo, Presidio, and Power Integrations — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    Organovo Affirms Key Clinical Development Goals; Company Reports Fiscal Third-Quarter 2019 Results

    Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019Submit first IND in calendar 2020 SAN DIEGO, Feb. 07, 2019 -- Organovo Holdings,.

  • GlobeNewswire

    Organovo Announces Release Date for Fiscal Third-Quarter 2019 Financial Results

    SAN DIEGO, Jan. 17, 2019 -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, February 7, 2019 at 5:00 p.m. Eastern Time (ET) to.

  • GlobeNewswire

    Organovo Partners With IIAM on Multi-Year Clinical Biomaterial Sourcing Agreement 

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that it has entered into a cell and tissue clinical sourcing agreement with the International Institute for the Advancement of Medicine (“IIAM”).  Under the terms of the agreement, IIAM will provide Organovo with donated organs that have not been utilized for transplantation with high potential benefit for generating the cell-based building blocks for Organovo’s therapeutic liver tissue development program.

  • GlobeNewswire

    Organovo Affirms Key Clinical Development Goals; Company Reports Fiscal Second-Quarter 2019 Results

    Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019Second orphan designation anticipated in first half of calendar 2019Submit first.